The current study included 29 patients who met the inclusion criteria outlined above, and received both [18F]Fluorocholine and [68Ga]Ga-PSMA PET/CT imaging within a maximum of 30 days of each other without any specific changes in concomitant prostate cancer treatment in this interval. This evidence concerns the gene FOLH1 and prostate carcinoma.